Allen S. Nielsen

Neurology

9961 Sierra Ave
Fontana, CA 92335

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.

Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.

Journal: Neurology

Published: April 09, 2026

De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy.

De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: March 19, 2026

Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.

Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.

Journal: Neurology

Published: December 22, 2025

Improving quality, affordability, and equity of multiple sclerosis care.

Improving quality, affordability, and equity of multiple sclerosis care.

Journal: Annals of clinical and translational neurology

Published: October 09, 2020

Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies.

Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: July 23, 2020

The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T2* mapping at 7 T MRI.

The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T2* mapping at 7 T MRI.

Journal: NeuroImage. Clinical

Published: August 18, 2016

Distinct T cell signatures define subsets of patients with multiple sclerosis.

Distinct T cell signatures define subsets of patients with multiple sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: June 01, 2016

Is the Relationship between Cortical and White Matter Pathologic Changes in Multiple Sclerosis Spatially Specific? A Multimodal 7-T and 3-T MR Imaging Study with Surface and Tract-based Analysis.

Is the Relationship between Cortical and White Matter Pathologic Changes in Multiple Sclerosis Spatially Specific? A Multimodal 7-T and 3-T MR Imaging Study with Surface and Tract-based Analysis.

Journal: Radiology

Published: September 04, 2015

Advances in the management of relapsing-remitting multiple sclerosis: role of oral dimethyl fumarate (BG-12).

Advances in the management of relapsing-remitting multiple sclerosis: role of oral dimethyl fumarate (BG-12).

Journal: Degenerative neurological and neuromuscular disease

Published: March 05, 2015

A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.

A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.

Journal: Brain : a journal of neurology

Published: February 15, 2015

Quantitative oxygen extraction fraction from 7-Tesla MRI phase: reproducibility and application in multiple sclerosis.

Quantitative oxygen extraction fraction from 7-Tesla MRI phase: reproducibility and application in multiple sclerosis.

Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

Published: July 14, 2014

Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS.

Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS.

Journal: Neurology

Published: July 19, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026